Bristol-Myers Squibb Co. shares edged up in premarket electronic trading today after a Goldman Sachs analyst upgraded the drug maker's stock because of its declining price. Bristol-Myers shares have been trading at annual lows over the …
along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb …
NEW YORK, Nov 15 (Reuters) - Bristol-Myers Squibb Co (BMY.N) said on Sunday it plans to split off its 83 percent stake in Mead Johnson Nutrition Company MJN.N in a deal that lets Bristol shareholders exchange their shares for Mead …
Bristol-Myers investors are paid a 2.45% dividend. Credit Suisse puts a $68 price target on the stock. The consensus target is much lower at $63.41. Shares closed trading Thursday at $60.23. Another top company in the health care …
And even though Trump had promised to go after pharmacy benefit managers—middlemen between drug-maker and insurers who take a cut of the …
Bristol-Myers Squibb will purchase all the outstanding capital stock of Flexus in an initial investment of $800 million with …
On Nov. 1, 2011, authorities say, Bristol-Myers Squibb executive Robert Ramnarine was called into ... For instance, Ramnarine allegedly ran the following terms on Nov. 2, 2011: “can stock option be traced to purchase insider trading.”
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed …
NEW YORK (Reuters) - Bristol-Myers Squibb Co (BMY.N) said on Sunday it plans to split off its 83 percent stake in Mead Johnson Nutrition Company MJN.N in a deal that lets Bristol shareholders exchange their shares for Mead Johnson …